期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
原子级电子断层成像技术进展及应用
1
作者 郑兴宇 吴起楷 +1 位作者 常人杰 杨尧 《电子显微学报》 CAS CSCD 北大核心 2023年第4期505-514,共10页
基于电子显微学的原子级三维重构技术对揭示材料的微观结构,加深材料结构和性能关系的理解具有极为重要的意义。原子级电子断层成像技术(atomic electron tomography,AET)作为当前最先进的三维重构技术之一,已先后成功表征了纳米颗粒中... 基于电子显微学的原子级三维重构技术对揭示材料的微观结构,加深材料结构和性能关系的理解具有极为重要的意义。原子级电子断层成像技术(atomic electron tomography,AET)作为当前最先进的三维重构技术之一,已先后成功表征了纳米颗粒中原子位置、晶体缺陷、早期形核过程中原子的动态变化及非晶态固体的三维原子结构。本文综述了AET的流程及应用的突破,以期望读者了解AET的基本原理流程和应用,并探讨未来AET在解决物理、化学、材料科学等领域基础问题的前景与挑战。 展开更多
关键词 三维重构 原子级电子断层成像技术 扫描透射电子显微镜 纳米材料
下载PDF
疏肝解郁方治疗慢性乙型肝炎伴抑郁疗效分析 被引量:2
2
作者 马拯华 吴其恺 +1 位作者 邓欣 王平 《中国肝脏病杂志(电子版)》 CAS 2019年第2期76-80,共5页
目的探讨中药疏肝解郁方治疗慢性乙型肝炎(chronic hepatitis B,CHB)伴抑郁的临床疗效.方法选取2016年1月至2018年6月深圳市第三人民医院收治的90例CHB伴抑郁患者为研究对象,采用随机数字表法分为治疗组和对照组,每组45例.对照组患者给... 目的探讨中药疏肝解郁方治疗慢性乙型肝炎(chronic hepatitis B,CHB)伴抑郁的临床疗效.方法选取2016年1月至2018年6月深圳市第三人民医院收治的90例CHB伴抑郁患者为研究对象,采用随机数字表法分为治疗组和对照组,每组45例.对照组患者给予恩替卡韦片治疗,治疗组患者给予恩替卡韦片联合中药疏肝解郁方治疗,疗程均为8周.比较治疗前后两组患者的丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)、汉密顿抑郁量表(Hamilton depression scale,HAMD)评分、皮质醇(cortisol,Cor)、白细胞介素-2(interleukin-2,IL-2)、自然杀伤(natural killer,NK)细胞及主要中医证候评分,并比较两组患者的治疗总有效率.结果治疗前两组患者的ALT、AST、HAMD评分、Cor、IL-2、NK细胞及主要中医证候评分差异均无统计学意义(P>0.05);治疗后两组患者ALT、AST、HAMD评分、Cor、各项中医证候评分较治疗前显著降低(P<0.01),IL-2和NK细胞水平显著升高(P<0.05);治疗组上述各项指标治疗前后差值显著大于对照组(P<0.05).对照组总有效率为73.3%(33/45);治疗组总有效率为93.3%(42/45),差异有统计学意义(z=6.238,P=0.013).结论疏肝解郁方可减轻患者抑郁症状,改善肝功能,纠正免疫功能紊乱,治疗CHB合并抑郁疗效显著. 展开更多
关键词 肝炎 乙型 慢性 抑郁 中药治疗 疏肝解郁方
下载PDF
血栓通穴位注射治疗新型冠状病毒肺炎临床研究
3
作者 李卓家 蔡庆贤 +7 位作者 袁静 谭晓华 吴其恺 唐升宏 邓欣 李海凤 马拯华 陈有国 《上海针灸杂志》 2021年第10期1182-1184,共3页
目的观察在西医综合治疗基础上联合血栓通穴位注射治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法将60例普通型COVID-19患者分为观察组和对照组,每组30例。对照组采用西医综合治疗,观察组在对照组治疗基础上,联合血栓通穴位注射治疗... 目的观察在西医综合治疗基础上联合血栓通穴位注射治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法将60例普通型COVID-19患者分为观察组和对照组,每组30例。对照组采用西医综合治疗,观察组在对照组治疗基础上,联合血栓通穴位注射治疗。观察两组临床疗效。结果观察组痊愈22例,转为重症0例;对照组痊愈13例,转为重症2例;两组痊愈率和重症转化率比较,差异有统计学意义(P<0.05),且观察组优于对照组。结论在西医综合治疗基础上,联合血栓通穴位注射可提高新型冠状病毒肺炎的痊愈率,降低重症转化率。 展开更多
关键词 针灸疗法 水针 穴位注射 新冠肺炎
下载PDF
Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B:Study Protocol for a Multi-Center,Double-Blind Randomized-Controlled Trial 被引量:11
4
作者 YE Yong-an LI Xiao-ke +19 位作者 ZHOU Da-qiao CHI Xiao-ling LI Qin WANG Li LU Bing-jiu MAO De-wen wu qi-kai WANG Xian-bo ZHANG Ming-xiang XUE Jing-dong LI Yong LU Wei GUO Jian-chun JIANG Feng ZHANG Xin-wei DU Hong-bo YANG Xian-zhao GUO Hui GAN Da-nan LI Zhi-guo 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2018年第9期653-660,共8页
Background: The domestic prevalence of chronic hepatitis B (CHB) in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot(s)ide analogues (NUCs) anti-hepatitis B virus (HBV) therapies ar... Background: The domestic prevalence of chronic hepatitis B (CHB) in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot(s)ide analogues (NUCs) anti-hepatitis B virus (HBV) therapies are widely applied despite the relatively low rate of seroconversion and high risk of drug-resistant mutation. More effective treatments for CHB deserve further explorations. Combined therapy of NUCs plus Chinese herbal medicine (CHM) is widely accepted in China, which is recognized as a prospective alternative approach. The study was primarily designed to confirm the hypothesis that Tiaogan-Yipi Granule (调肝益脾颗粒, TGYP) or Tiaogan-Jianpi-Jiedu Granule (调肝健脾解毒颗粒, TGJPJD) plus entecavir tablet (ETV) was superior over ETV monotherapy in enhancing HBeAg loss rate. Methods: The study was a nationwide, large-scale, multi-center, double-blind, randomized, placebo-controlled trial with a designed duration of 108 weeks. A total of 16 hospitals and 596 eligible Chinese HBeAg positive CHB patients were enrolled from November 2012 to September 2013 and randomly allocated into 2 groups in 1:1 ratio via central randomization system: experimental group (EG) and control group (CG). Subjects in EG received CM formulae (TGYP or TGJPJD, 50 g per dose, twice daily) plus ETV tablet (or ETV placebo) 0.5 mg per day in the first 24 weeks (stage 1), and CHM granule plus ETV tablet (0.5 mg per day) from week 25 to 108 (stage 2). Subjects in CG received CHM Granule placebo plus E'IV tablet (0.5 mg per day) for 108 weeks throughout the trial. The assessments of primary outcomes (HBV serum markers and HBV-DNA) were conducted by a third-party College of American Pathologists (CAP) qualified laboratory. Adverse effects were observed in the hospitals of recruitment. Discussion: The study was designed to compare the curative effect of CM plus E'IV and ETV monotherapy in respect of HBeAg loss, which is recognized by the European Association for the Study of the Liver as "a valuable endpoint". We believe this trial could provide a reliable status for patients' "joumey" towards durable responses after treatment discontinuation. The trial was registered before recruitment on Chinese Clinical trial registry (No. ChiCTR-TRC-12002784, Version 1.0, 2015/12/23). 展开更多
关键词 chronic hepatitis B Chinese herbal medicine Tiaogan-Jianpi-Jiedu Granule Tiaogan-Yipi Granule protocol randomized-controlled trial
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部